公开(公告)号：US20230063805A1

公开(公告)日：2023-03-02

申请号：US17846830

申请日：2022-06-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  C07D211/36 ,  C07D405/06 ,  A61P25/26 ,  C07D409/10 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230042358A1

公开(公告)日：2023-02-09

申请号：US17413469

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Jun CHIBA ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC: C07D455/02 ,  A61P25/26 ,  C07D471/04 ,  C07D217/24 ,  C07D239/90 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D498/04 ,  C07D417/06 ,  C07D401/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20210179603A1

公开(公告)日：2021-06-17

申请号：US17176861

申请日：2021-02-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D417/12 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D413/14 ,  C07D231/14 ,  C07D333/40 ,  C07D285/08 ,  C07D285/135 ,  C07D231/12 ,  C07D277/56 ,  C07D409/14 ,  C07D413/12 ,  C07D307/81

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20190040010A1

公开(公告)日：2019-02-07

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OHYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  C07D401/10 ,  C07D401/06 ,  C07D207/14 ,  C07D405/10 ,  C07D417/06 ,  C07D405/12 ,  C07D413/06 ,  C07D401/14 ,  C07D205/04 ,  C07D403/06 ,  C07D417/14 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20180079756A1

公开(公告)日：2018-03-22

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei IKEDA ,  Tatsuki KOIKE ,  Jumpei AIDA ,  Makoto FUSHIMI ,  Tomokazu KUSUMOTO ,  Hideyuki SUGIYAMA ,  Masako MIYAZAKI ,  Hidekazu TOKUHARA ,  Yasushi HATTORI ,  Makoto KAMATA

IPC: C07D498/04 ,  C07D401/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D498/04 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383 ,  C07D401/06 ,  C07D401/10 ,  C07D413/06 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C12N9/99

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20170001994A1

公开(公告)日：2017-01-05

申请号：US15270863

申请日：2016-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/12 ,  C07D285/135 ,  C07D409/12 ,  C07D413/12 ,  C07D407/12 ,  C07D213/82 ,  C07D417/14 ,  C07D333/38 ,  C07D231/14 ,  C07D307/79

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US20150291577A1

公开(公告)日：2015-10-15

申请号：US14682695

申请日：2015-04-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC: C07D417/14 ,  C07D409/12 ,  C07D333/38 ,  C07D407/12 ,  C07D213/82 ,  C07D417/12 ,  C07D307/79

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供具有赖氨酸特异性脱甲基酶-1抑制作用的化合物，可用作精神分裂症，发育障碍，特别是具有智力障碍的疾病（例如自闭症谱系，Rett综合征， 唐氏综合征，歌舞伎综合征，脆性X综合征，克莱斯特综合征，1型神经纤维瘤病，Noonan综合征，结节性硬化症），神经变性疾病（如阿尔茨海默氏病，帕金森病，脊髓小脑变性（例如，牙周性苍白球萎缩症）和亨廷顿疾病）），癫痫 （例如，Dravet综合征）或药物依赖性等。 由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC classification number: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230037557A1

公开(公告)日：2023-02-09

申请号：US17780125

申请日：2020-11-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yoshiteru ITO ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Tatsuki KOIKE ,  Norihito TOKUNAGA ,  Eiji KIMURA ,  Alexander Martin PAWLICZEK ,  Marilena PIRA ,  Javier MIGUELEZ-RAMOS

IPC: C07D471/04 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20220017514A1

公开(公告)日：2022-01-20

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC: C07D471/04 ,  C07D231/56 ,  C07D277/64 ,  C07D215/38 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.